Recommendation ID
NG50/3
Question

What is the clinical and cost effectiveness of non-selective beta-blockers for the primary prevention of decompensation in people with compensated cirrhosis and signs of clinically significant portal hypertension from non-invasive tests (such as tests to measure liver stiffness, or biomarkers)?

Any explanatory notes
(if applicable)

For a short explanation of why the committee made this recommendation for research, see the rationale section on primary prevention of decompensation .

Full details of the evidence and the committee's discussion are in evidence review C: clinical and cost effectiveness of non-selective beta-blockers for the primary prevention of decompensation in people with compensated cirrhosis.


Source guidance details

Comes from guidance
Cirrhosis in over 16s: assessment and management
Number
NG50
Date issued
July 2016

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No  
Last Reviewed 11/01/2024